AIMS/HYPOTHESIS: We investigated whether random proinsulin levels and proinsulin:C-peptide ratio (PI:C) complement immune and genetic markers for identifying relatives at high risk of type 1 diabetes. MATERIALS AND METHODS: During an initial sampling, random glycaemia, proinsulin, PI:C and HLA DQ genotype were determined in 561 non-diabetic first-degree relatives who had been positive for islet autoantibodies on one or more occasions and in 561 age- and sex-matched persistently antibody-negative relatives. RESULTS: During follow-up (median 62 months), 46 relatives with antibodies at entry developed type 1 diabetes. At baseline, antibody-positive relatives (n=338) had higher PI:C values (p<0.001) than antibody-negative subjects with (n=223) or subjects without (n=561) later seroconversion. Proinsulin and PI:C were graded according to risk of diabetes as expressed by positivity for (multiple) antibodies or IA-2 antibodies, especially in persons carrying the high-risk HLA DQ2/DQ8 genotype and in prediabetic relatives. In the presence of multiple or IA-2 antibodies, a PI:C ratio exceeding percentile 66 of all antibody-negative relatives at entry (n=784) conferred a 5-year diabetes risk of 50% and 68%, respectively (p<0.001 vs 13% for same antibody status with PI:C<percentile 66). Cox regression analysis confirmed random PI:C as an independent predictor of the risk of diabetes (p< or =0.001). CONCLUSIONS/ INTERPRETATION: Random proinsulin and PI:C represent dynamic markers of the state of beta cell function that complement immune markers in identifying relatives who are at homogeneously high risk of contracting type 1 diabetes and are therefore eligible for secondary prevention trials.
AIMS/HYPOTHESIS: We investigated whether random proinsulin levels and proinsulin:C-peptide ratio (PI:C) complement immune and genetic markers for identifying relatives at high risk of type 1 diabetes. MATERIALS AND METHODS: During an initial sampling, random glycaemia, proinsulin, PI:C and HLA DQ genotype were determined in 561 non-diabetic first-degree relatives who had been positive for islet autoantibodies on one or more occasions and in 561 age- and sex-matched persistently antibody-negative relatives. RESULTS: During follow-up (median 62 months), 46 relatives with antibodies at entry developed type 1 diabetes. At baseline, antibody-positive relatives (n=338) had higher PI:C values (p<0.001) than antibody-negative subjects with (n=223) or subjects without (n=561) later seroconversion. Proinsulin and PI:C were graded according to risk of diabetes as expressed by positivity for (multiple) antibodies or IA-2 antibodies, especially in persons carrying the high-risk HLA DQ2/DQ8 genotype and in prediabetic relatives. In the presence of multiple or IA-2 antibodies, a PI:C ratio exceeding percentile 66 of all antibody-negative relatives at entry (n=784) conferred a 5-year diabetes risk of 50% and 68%, respectively (p<0.001 vs 13% for same antibody status with PI:C<percentile 66). Cox regression analysis confirmed random PI:C as an independent predictor of the risk of diabetes (p< or =0.001). CONCLUSIONS/ INTERPRETATION: Random proinsulin and PI:C represent dynamic markers of the state of beta cell function that complement immune markers in identifying relatives who are at homogeneously high risk of contracting type 1 diabetes and are therefore eligible for secondary prevention trials.
Authors: K Hostens; D Pavlovic; Y Zambre; Z Ling; C Van Schravendijk; D L Eizirik; D G Pipeleers Journal: J Clin Invest Date: 1999-07 Impact factor: 14.808
Authors: F K Gorus; P Goubert; C Semakula; C L Vandewalle; J De Schepper; A Scheen; M R Christie; D G Pipeleers Journal: Diabetologia Date: 1997-01 Impact factor: 10.122
Authors: F K Gorus; C L Vandewalle; H Dorchy; P Van Crombrugge; F C Schuit; D G Pipeleers Journal: J Clin Endocrinol Metab Date: 1994-05 Impact factor: 5.958
Authors: Milca Asanghanwa; Frans K Gorus; Ilse Weets; Bart V der Auwera; Folefac Aminkeng; Eric Mbunwe; Patrick Goubert; Katrijn Verhaeghen; Eugene Sobngwi; Janet M Wenzlau; John C Hutton; Daniel G Pipeleers; Bart Keymeulen; Jean-Claude N Mbanya; Chris van Schravendijk Journal: Diabetes Res Clin Pract Date: 2013-11-20 Impact factor: 5.602
Authors: Quinn Dufurrena; Nils Bäck; Richard E Mains; Louis Hodgson; Herbert Tanowitz; Prashant Mandela; Elizabeth Eipper; Regina Kuliawat Journal: J Mol Endocrinol Date: 2018-11-01 Impact factor: 5.098
Authors: Laura M Jacobsen; Brittney N Newby; Daniel J Perry; Amanda L Posgai; Michael J Haller; Todd M Brusko Journal: Curr Diab Rep Date: 2018-08-30 Impact factor: 4.810
Authors: Emily K Sims; Carmella Evans-Molina; Sarah A Tersey; Decio L Eizirik; Raghavendra G Mirmira Journal: Diabetologia Date: 2018-08-15 Impact factor: 10.122
Authors: Renecia A Watkins; Carmella Evans-Molina; Jennifer K Terrell; Kathleen H Day; Lynette Guindon; Ivan A Restrepo; Raghavendra G Mirmira; Janice S Blum; Linda A DiMeglio Journal: Transl Res Date: 2015-09-04 Impact factor: 7.012
Authors: J De Grijse; M Asanghanwa; B Nouthe; N Albrecher; P Goubert; I Vermeulen; S Van Der Meeren; K Decochez; I Weets; B Keymeulen; V Lampasona; J Wenzlau; J C Hutton; D Pipeleers; F K Gorus Journal: Diabetologia Date: 2009-11-29 Impact factor: 10.122